[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].
Fiche publication
Date publication
mai 2019
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MAYEUR Didier
Tous les auteurs :
Jovenin N, Eche-Gass A, Chèze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scotté F,
Lien Pubmed
Résumé
Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti-emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) "Outperform" prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed.
Mots clés
Antineoplastic agents, Guidelines, Nausea, Nausée, Recommandations, Soins de support, Supportive care, Traitements anticancéreux, Vomissement, Vomiting
Référence
Bull Cancer. 2019 05;106(5):497-509